My ePortfolio Register   

IMPAKT 2017 /
Mutational landscapes in pregnant and non-pregnant breast cancer

4th - 6th May 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 660

Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Prof Loibl speaks with ecancer at IMPAKT 2017 about the differing genetic backgrounds and susceptibilities of breast cancer in patients who are pregnant.

She describes results from next-generation sequencing of samples, compared to data in The Cancer Genome Atlas, noting that the samples assessed were taken from much younger women.

Among the differences in gene expression, Prof Loibl highlights difference in PI3K and p53 mutation levels.

Prof Loibl summarises treatment schedules for pregnant breast cancer patients, cautioning against under-treatment of aggressive tumours and over-treatment of HR2 patients.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence